|
1
|
Coate LE, John T, Tsao MS and Shepherd FA:
Molecular predictive and prognostic markers in non-small-cell lung
cancer. Lancet Oncol. 10:1001–1010. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kerr KM, Bubendorf L, Edelman MJ,
Marchetti A, Mok T, Novello S, O'Byrne K, Stahel R, Peters S, Felip
E, et al: Second ESMO consensus conference on lung cancer:
Pathology and molecular biomarkers for non-small-cell lung cancer.
Ann Oncol. 25:1681–1690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
O'Byrne KJ, Gatzemeier U, Bondarenko I,
Barrios C, Eschbach C, Martens UM, Hotko Y, Kortsik C, Paz-Ares L,
Pereira JR, et al: Molecular biomarkers in non-small-cell lung
cancer: A retrospective analysis of data from the phase 3 FLEX
study. Lancet Oncol. 12:795–805. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chatziandreou I, Tsioli P, Sakellariou S,
Mourkioti I, Giannopoulou I, Levidou G, Korkolopoulou P, Patsouris
E and Saetta AA: Comprehensive molecular analysis of NSCLC;
Clinicopathological Associations. PLoS One. 10:e01338592015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dearden S, Stevens J, Wu YL and Blowers D:
Mutation incidence and coincidence in non small-cell lung cancer:
Meta-analyses by ethnicity and histology (mutMap). Ann Oncol.
24:2371–2376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
D'Arcangelo M and Cappuzzo F: K-Ras
mutations in non-small-cell lung cancer: Prognostic and predictive
value. ISRN Mol Biol. 2012:8373062012.PubMed/NCBI
|
|
7
|
Aisner DL and Marshall CB: Molecular
pathology of non-small cell lung cancer: A practical guide. Am J
Clin Pathol. 138:332–346. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Boch C, Kollmeier J, Roth A,
Stephan-Falkenau S, Misch D, Grüning W, Bauer TT and Mairinger T:
The frequency of EGFR and KRAS mutations in non-small cell lung
cancer (NSCLC): Routine screening data for central Europe from a
cohort study. BMJ Open. 3:pii:e0025602013. View Article : Google Scholar
|
|
9
|
Eberhard DA, Giaccone G and Johnson BE:
Non-Small-Cell lung Cancer Working Group: Biomarkers of response to
epidermal growth factor receptor inhibitors in Non-Small-Cell Lung
Cancer Working Group: Standardization for use in the clinical trial
setting. J Clin Oncol. 26:983–994. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gahr S, Stoehr R, Geissinger E, Ficker JH,
Brueckl WM, Gschwendtner A, Gattenloehner S, Fuchs FS, Schulz C,
Rieker RJ, et al: EGFR mutational status in a large series of
Caucasian European NSCLC patients: Data from daily practice. Br J
Cancer. 109:1821–1828. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kosaka T, Yatabe Y, Endoh H, Kuwano H,
Takahashi T and Mitsudomi T: Mutations of the epidermal growth
factor receptor gene in lung cancer: Biological and clinical
implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Eng J Med.
350:2129–2139. 2004. View Article : Google Scholar
|
|
13
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Souglakos J: Customizing chemotherapy in
non-small cell lung cancer: The promise is still unmet. Trans Lung
Cancer Res. 4:653–655. 2015.
|
|
18
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Eng J Med. 362:2380–2388. 2010. View Article : Google Scholar
|
|
19
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Eng J Med. 361:947–957. 2009. View Article : Google Scholar
|
|
21
|
Sequist LV, Yang JC, Yamamoto N, O'Byrne
K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al:
Phase III study of afatinib or cisplatin plus pemetrexed in
patients with metastatic lung adenocarcinoma with EGFR mutations. J
Clin Oncol. 31:3327–3334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang
Y, Li W, Hou M, Shi JH, Lee KY, et al: Afatinib versus cisplatin
plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations
(LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet
Oncol. 15:213–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ettinger DS, Akerley W, Bepler G, Blum MG,
Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, et
al: Non-small cell lung cancer. J Natl Compr Canc Netw. 8:740–801.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lindeman NI, Cagle PT, Beasley MB, Chitale
DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS,
Squire J, et al: Molecular testing guideline for selection of lung
cancer patients for EGFR and ALK tyrosine kinase inhibitors:
Guideline from the College of American pathologists, international
association for the study of lung cancer and Association for
Molecular Pathology. Arch Pathol Lab Med. 137:828–860. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Marchetti A, Normanno N AIOM-SIAPEC-IAP,
Pinto C, Taddei GL, Adamo V, Ardizzoni A, Botti G, Bardelli A,
Comin C, et al: Recommendations for mutational analysis of EGFR in
lung carcinoma. Pathologica. 102:119–126. 2010.(In English,
Italian). PubMed/NCBI
|
|
28
|
Pirker R, Herth FJ, Kerr KM, Filipits M,
Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, et
al: Consensus for EGFR mutation testing in non-small cell lung
cancer: Results from a European workshop. J Thorac Oncol.
5:1706–1713. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/American thoracic society/European respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Westwood M, Joore M, Whiting P, van Asselt
T, Ramaekers B, Armstrong N, Misso K, Severens J and Kleijnen J:
Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation
testing in adults with locally advanced or metastatic non-small
cell lung cancer: A systematic review and cost-effectiveness
analysis. Health Technol Assess. 18:1–166. 2014. View Article : Google Scholar
|
|
31
|
Keedy VL, Temin S, Somerfield MR, Beasley
MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA and
Giaccone G: American Society of Clinical Oncology provisional
clinical opinion: Epidermal growth factor receptor (EGFR) Mutation
testing for patients with advanced non-small-cell lung cancer
considering first-line EGFR tyrosine kinase inhibitor therapy. J
Clin Oncol. 29:2121–2127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Krawczyk P, Chorostowska-Wynimko J,
Dziadziuszko R, Jassem J, Krzakowski M, Langfort R, Puacz E, Wasąg
B and Wojas-Krawczyk K: Methodological recommendations for the
diagnostics of EGFR gene mutations and ALK gene rearrangement in
the selection of non-small-cell lung cancer patients to molecularly
targeted therapies. Pneumonol Alergol Pol. 82:437–444. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Krawczyk P, Ramlau R, Chorostowska-Wynimko
J, Powrózek T, Lewandowska MA, Limon J, Wasąg B, Pankowski J,
Kozielski J, Kalinka-Warzocha E, et al: The efficacy of EGFR gene
mutation testing in various samples from non-small cell lung cancer
patients: A multicenter retrospective study. J Cancer Res Clin
Oncol. 141:61–68. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ramlau R, Cufer T, Berzinec P,
Dziadziuszko R, Olszewski W, Popper H, Bajcic P, Dušek L,
Zbozinkova Z and Pirker R: INSIGHT study team: Epidermal growth
factor receptor mutation-positive non-small-cell lung cancer in the
real-world setting in central Europe: The INSIGHT Study. J Thorac
Oncol. 10:1370–1374. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
R Development Core Team: R: A language and
environment for statistical computingR Foundation for Statistical
Computing. Vienna: 2014
|
|
37
|
Santini D, Barni S, Intagliata S, Falcone
A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli
F, et al: Natural history of non-small-cell lung cancer with bone
metastases. Sci Rep. 5:186702015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Petrelli F, Borgonovo K, Cabiddu M and
Barni S: Efficacy of EGFR tyrosine kinase inhibitors in patients
with EGFR-mutated non-small-cell lung cancer: A meta-analysis of 13
randomized trials. Clin Lung Cancer. 13:107–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Barlesi F, Mazieres J, Merlio JP,
Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I,
Westeel V, et al: Routine molecular profiling of patients with
advanced non-small-cell lung cancer: Results of a 1-year nationwide
programme of the French Cooperative Thoracic Intergroup (IFCT).
Lancet. 387:1415–1426. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Beau-Faller M, Prim N, Ruppert AM,
Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet
JL, Rouquette I, et al: Rare EGFR exon 18 and exon 20 mutations in
non-small-cell lung cancer on 10 117 patients: A multicentre
observational study by the French ERMETIC-IFCT network. Ann Oncol.
25:126–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Powrózek T, Krawczyk P, Ramlau R, Sura S,
Wojas-Krawczyk K, Kucharczyk T, Walczyna B, Szumiło J,
Szyszka-Barth K, Milecki P, et al: EGFR gene mutations in patients
with adenosquamous lung carcinoma. Asia Pac J Clin Oncol.
10:340–345. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Krawczyk P, Nicoś M, Ramlau R, Powrózek T,
Wojas-Krawczyk K, Sura S, Jarosz B, Szumiło J, Warda E,
Mazurkiewicz T, et al: The incidence of EGFR-activating mutations
in bone metastases of lung adenocarcinoma. Pathol Oncol Res.
20:107–112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lee CK, Brown C, Gralla RJ, Hirsh V,
Thongprasert S, Tsai CM, Tan EH, Ho JC, da Chu T, Zaatar A, et al:
Impact of EGFR inhibitor in non-small cell lung cancer on
progression-free and overall survival: A meta-analysis. J Natl
Cancer Inst. 105:595–605. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Girard N, Sima CS, Jackman DM, Sequist LV,
Chen H, Yang JC, Ji H, Waltman B, Rosell R, Taron M, et al:
Nomogram to predict the presence of EGFR activating mutation in
lung adenocarcinoma. Eur Respir J. 39:366–372. 2012. View Article : Google Scholar : PubMed/NCBI
|
